PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “ECOG”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources
PubMed1988

Continuous infusion homoharringtonine (NSC 141633) in refractory acute nonlymphocytic leukemia. An ECOG pilot study.

Single-agent homoharringtonine (HH) was evaluated as induction therapy in 20 patients with advanced acute nonlymphocytic leukemia (ANLL) in a pilot study of the Eastern Cooperative Oncology Group (ECOG). HH was given by continuous intravenous (i.v.) infusion at 3.5 mg/m2 on the first day and at 6.0 mg/m2/day on days 2-8. Fourteen men and six women with a median age of 43 years were treated. Sixteen patients had clearing of peripheral blasts, 10 patients achieved marrow hypoplasia, and 2 patients had progressive disease. No complete remission occurred. Drug-induced hypotension was the most significant toxicity, causing a delay in treatment in 8 patients. The median survival was 15 weeks (range 1-65 weeks) from the start of HH treatment. Despite a definite antileukemic effect, HH as a single agent cannot be recommended as a useful salvage regimen in patients with far advanced ANLL.

Adolescent↗
PubMed1988

ECOG phase II trials of MGBG, chlorozotocin, COM multidrug therapy in advanced measurable colorectal cancer.

The Eastern Cooperative Oncology Group (ECOG) entered 326 patients with advanced measurable colorectal cancer into four phase II drug or drug combination trials. Previously treated and chemotherapy-naive patients were eligible. Chlorozotocin was administered to 83 patients (51 previously treated), methyl-glyoxal-bis-guanylhydrozone (MGBG) to 90 patients (58 previously treated), and two regimens of the three-drug combination of cyclophosphamide, vincristine, and methotrexate (COM) to 153 patients (120 previously treated). The multidrug regimen had been developed specifically for previously treated patients. In this trial, chemotherapy-naive patients were no more likely to respond than were members of the previously-treated group. Even among previously untreated patients, response rates did not exceed 10% in any of these phase II programs. They are not recommended for further trials in patients with colorectal cancers.

Adenocarcinoma↗
PubMed2000

Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) Study.

Patients with non-Hodgkin's lymphoma (NHL) who fail initial therapy have a poor prognosis. We conducted a phase II study to determine the efficacy and toxicity of didemnin B, a non-myelosuppressive marine compound, in patients with NHL who relapsed or progressed after receiving one or two previous chemotherapy regimens. Fifty-one eligible patients were registered on this phase II study. Twenty-nine patients had intermediate or high grade (IG/HG) disease and 22 patients had low grade (LG) disease. Twenty-five patients received didemnin B at a dose of 6.3 mg/m2 and the remainder received 5.6 mg/m2, administered intravenously every 28 days. The patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and biopsy-proven relapsed disease. Objective responses were observed in two (7%) patients (one complete remission [CR] and one partial remission [PR]) with IG/HG disease and five (23%) patients (one CR and four PR) with LG disease. Patients with IG/HG disease had a median time to treatment failure (TTF) of 1.6 months and a median survival of 8.0 months. In contrast, the group with LG disease had a median TTF of 4.6 months and a median survival of 2.7 years. There were five grade V, 12 grade IV, and 57 grade III toxicities. Didemnin B appears to have modest activity in low grade NHL. However, the drug has considerable toxicity in this population of patients.

Adult↗
PubMed2006

ECoG factors underlying multimodal control of a brain-computer interface.

Most current brain-computer interface (BCI) systems for humans use electroencephalographic activity recorded from the scalp, and may be limited in many ways. Electrocorticography (ECoG) is believed to be a minimally-invasive alternative to electroencephalogram (EEG) for BCI systems, yielding superior signal characteristics that could allow rapid user training and faster communication rates. In addition, our preliminary results suggest that brain regions other than the sensorimotor cortex, such as auditory cortex, may be trained to control a BCI system using similar methods as those used to train motor regions of the brain. This could prove to be vital for users who have neurological disease, head trauma, or other conditions precluding the use of sensorimotor cortex for BCI control.

Adult↗
PubMed2005

Selecting parameters for phase space reconstruction of the electrocorticogram (ECoG).

The selection of parameters for phase space reconstruction of empirically observed data has been a source of criticism when estimating the correlation dimension (D2) from observed data rather than from the solution of differential equations, when analyzing noisy and potentially non-stationary signals, such as the electroencephalogram (EEG). The largely arbitrary selection of the time-delay reconstruction (T) of temporal dynamics, and for the embedding (M) of these series, has been widely criticized. This study adopted an analytic and statistical framework within which the scaling behavior of D2 with respect to T and M, could be examined over five data lengths (N = 4096, 8192, 12288, 16384, and 20480) over an 8 x 8 grid of cat EEG. It was found that D2 was invariant over all data lengths only within a very narrow T range (T = 10-16) for M = 4. A statistically significant T by M interaction was found using multiple analysis of variance, with D2 being highly correlated over T as a function of M. Finally, an examination of phase-randomized surrogates indicated that statistically significant differences existed between EEG and phase-randomized surrogates over all data lengths, with time delays (T = 10-16), indicating that the D2 for EEG is phase-dependent when it is invariant with respect to data length. The implications of these findings are discussed with respect to current models of ECoG generation, and their implication with respect to the integration in the brain.

Analysis of Variance↗
PubMed2006

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.

Pretreatment cytogenetics is a known predictor of outcome in hematologic malignancies. However, its usefulness in adult acute lymphoblastic leukemia (ALL) is generally limited to the presence of the Philadelphia (Ph) chromosome because of the low incidence of other recurrent abnormalities. We present centrally reviewed cytogenetic data from 1522 adult patients enrolled on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. The incidence and clinical associations for more than 20 specific chromosomal abnormalities are presented. Patients with a Ph chromosome, t(4;11)(q21;q23), t(8;14)(q24.1;q32), complex karyotype (5 or more chromosomal abnormalities), or low hypodiploidy/near triploidy (Ho-Tr) all had inferior rates of event-free and overall survival when compared with other patients. In contrast, patients with high hyperdiploidy or a del(9p) had a significantly improved outcome. Multivariate analysis demonstrated that the prognostic relevance of t(8;14), complex karyotype, and Ho-Tr was independent of sex, age, white cell count, and T-cell status among Ph-negative patients. The observation that Ho-Tr and, for the first time, karyotype complexity confer an increased risk of treatment failure demonstrates that cytogenetic subgroups other than the Ph chromosome can and should be used to risk stratify adults with ALL in future trials.

Adult↗
PubMed2003

Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study.

This study, a phase III multicenter randomized trial opened by ECOG in April 1983 and closed in June 1986 was designed to evaluate whether a combination of doxorubicin and an intravenous formulation of diethylstilbestrol diphosphate (DES) was superior to doxorubicin alone in men with hormone refractory prostate cancer. All patients received doxorubicin at a dose of 50 mg/m2 iv every 3 wk either alone or with 1 g DES iv daily for 5 d followed by 1 g iv twice weekly for four cycles (12 wk). The 51 evaluable patients with visceral metastases displayed a significantly increased response rate (27% vs 63%) on the combined therapy arm (p = 0.04). However, the 111 evaluable patients with osseous disease exhibited no difference in response rate between either arm with a p-value of >0.99. Similarly, clinical response rates revealed no difference between the two arms. Cases of cardiac toxicity graded as severe, life threatening, or lethal in the combined therapy arm were 10 times more frequent in the combined-therapy arm than in the doxorubicin-alone group (6.75% compared to 0.7%). This difference was statistically significant (p = 0.0041). All of the cases of superficial and deep venous thrombosis occurred on the combined-therapy arm. There were no other significant differences in the numbers of grade 3 or 4 toxic events. The most common toxicity was hematologic. Failure-free survival duration did reach statistical significance in the combined-therapy group (p = 0.012), although the actual durations were short (2.6-3.2 mo). There was no difference in overall survival between the two groups.

Aged↗
PubMedDate not supplied

Electrocochleography (ecog) in sensorineural deafness.

We examined 340 normal ears and cases of sensorineural deafness with electrocochleography using click stimuli (duration: 0.5 standard deviation of a population; repetition rate: plus or minus 10/sec; N=1 000, alternately positive and negative; analysis time: 31 standard deviation of a population). The latency of N-1 is a function of the sound pressure level and of the age of the subject. The intensity of N-1 (in mu-v) is a function of hearing level and is influenced by the presence of recruitment. The pure-tone audiogram is a function of the ECOG threshold and of the shape of the reaction obtained at maximal stimulation intensity.

Acoustic Stimulation↗
PubMed1990

Phase II trial of methylglyoxal-bis(guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) study.

Twenty patients with refractory multiple myeloma were treated with methylglyoxal-bis(guanylhydrazone) (MGBG), an inhibitor of polyamine synthesis. MGBG 500 mg/m2 was administered on days 1 and 8, and then every 14 days. The dose was escalated to 600 mg/m2 on day 22, as tolerated. Of 14 evaluable patients, none met ECOG criteria for an objective response. The major toxicity was hematologic and related infections. MGBG demonstrated insufficient activity in the treatment of refractory multiple myeloma to warrant further study.

Adult↗
PubMedDate not supplied

Correlation of tumor p53 and PCNA with response and survival of glioblastoma in patients treated with an ECOG protocol of pre-irradiation chemotherapy.

BACKGROUND: The ability to predict treatment responsiveness and survival of patients with glioblastoma multiforme, the most malignant and most common primary brain tumor, would be a valuable asset. Tumor and proliferation markers such as p53 and PCNA have been immunohistochemically defined and have been useful in other tumors in determining prognosis. Therefore, the authors studied the correlation of responsiveness to treatment, time to progression and survival with p53 and PCNA labeling indices in a pre-irradiation chemotherapy study of the glioblastoma multiforme. METHODS: Immunohistopathology for labeling indices for p53 and PCNA using formalin-fixed, paraffin-embedded tissue from the glioblastomas of 23 patients entered into a phase II ECOG trial of pre-irradiation chemotherapy were defined using the streptavidin-peroxidase technique with AEC chromogen. The labeling indices were correlated with response to treatment time to progression and overall survival. Most patients received three cycles of BCNU for three days over three months and cisplatin monthly for three days over three months prior to external beam irradiation. RESULTS: There were no significant differences in treatment response, time to progression or overall survival in glioblastoma, patients with positive p53 labeling index (> 5%) versus a negative p53 labeling index (< or = 5%) or positive PCNA labeling (> 10%) versus a negative labeling index (< or = 10%) or any combination of P53 and PCNA labeling indices. CONCLUSIONS: Using this protocol of pre-irradiation chemotherapy, p53 and PCNA labeling indices in the glioblastoma multiforme did not predict treatment benefit.

Adult↗
PubMed1992

Influence of phenobarbital on ECoG phenomena induced by metrazol in rats during ontogenesis.

Effect of phenobarbital (PhB, 20 and/or 40 mg/kg) on epileptic ECoG phenomena induced by metrazol was studied in acute experiments in rats aged 7, 12, 18, 25 and 90 days. Fractionated administration of metrazol (20 mg/kg i.p. each 300 s) was used to quantify the effects of PhB. First signs of metrazol action (sharp elements and/or rhythmic metrazol activity) were not reliably influenced by PhB. On the contrary, the latency of the first EEG seizures as well as of the first generalized EEG seizures was prolonged and thus a dose necessary for their elicitation was increased in all age groups. These differences reached statistical significance in 12-, 18- and 25-day-old rats. A lack of effect of PhB against the rhythmic metrazol activity supports the adequacy of this activity as a model of human absences. Differences between the development of antiepileptic and hypnotic effects of PhB (described earlier) suggest two different mechanisms of action.

Aging↗
PubMedDate not supplied

[The ECoG of rats with genetic catalepsy].

Electrographic study was carried out in Wistar rats and the rats of genetical catalepsy (GC) strain. In contrast to Wistar rats epileptiform activity was observed in ECoG of GC rats being enhanced at the transition to a cataleptic state. Analysis of spectra and coherence of EEG revealed the presence of interhemispheric brain asymmetry in all the rats. In some frequency bands in GC rats inversion of interhemispheric asymmetry was found, which had been characteristic for Wistar strain. The highest interhemispheric synchronization of biopotentials was observed in the frontal cortical areas in GC rats and in the occipital areas in those of Wistar strain.

Animals↗
PubMed1992

A comparison between the Rappaport Classification and Working Formulation in cooperative group trials: the ECOG experience.

The Working Formulation (WF) for the classification of non-Hodgkin's lymphomas was shown to be reproducible and clinically relevant in the original study. However, it has not yet been tested by an NCI-supported cooperative clinical oncology group. As a result, the Hematopathology Subcommittee of the Eastern Cooperative Oncology Group (ECOG) undertook a retrospective study to compare concordance and practical utility between the WF and the Rappaport Classification (RC). Data indicate that with appropriate modifications to minimize unclassifiable lymphomas, the WF can be effectively utilized in cooperative clinical oncology groups.

Humans↗
PubMed2006

[Changes in the rabbit brain cortex redox potential accompaning episodes of ECoG-arousal during slow-wave sleep].

Local cortex E variations are well expressive indices of rate and peculiarities of energy metabolism. The brain E is determined by the ratio of processes occurring in two energy compartments in glycolysis, in whish glucose is split without oxygen utilization and in oxidative metabolism. In the present investigation, the brain cortex E changes were recorded with implanted platinum electrodes during slow wave sleep. Under such conditions, the E lowering detects acceleration in glycolytic compartment, whereas the E local rising shows acceleration in oxidative metabolism in the tissue surrounding the electrode. Earlier in rats, we have found that E significantly lowered in metabolic active cortical sites during episodes of SWS, and supposed that acceleration of glycolysis increased. Slow oscillations (a 20-40-sec prolongation of the amplitude up to several dozens millivolts) appeared at the same time. We considered these E slow oscillations to reflect changes in the rate in compartment of glycolysis. In this research, we have found the E slow oscillations to be created by regular episodes of ECoG-arousal which were accompanied by E decreases, i. e. by acceleration in glycolysis. We think the data presented show existence of functional system supporting a low level of arousal. As in any complex system with feed back connections, this system works in oscillatory regime.

Animals↗
PubMed1989

[Inhibitory effect of electroacupuncture on cAMP induced ECOG epileptiform waves].

In conscious rabbits, injection of cAMP (100 micrograms in 100 microliters, icv) elicited high-amplitude and high-frequency epileptiform seizure pattern of ECoG. The epileptic waves were inhibited by electro-acupuncturing bilateral "Zusanli" Points. During and after the cessation of electro-acupuncture the frequency, amplitude and duration of epileptiform discharges decreased significantly, the seizure waves even disappeared completely. The frequency and amplitude of epileptic waves showed significant difference in comparison with those of the non-electroacupuncture group (p less than 0.001 and p less than 0.01 respectively), the duration of epileptic waves shortened by 58.18-66.88%. The results suggested that electroacupuncture has antiepileptic action on c-AMP induced experimental epileptic seizure.

Acupuncture Therapy↗
PubMed1983

The effects of penicillin on the ECoG of rabbit.

The effects of non-convulsive doses of i.v. penicillin (1.100.000/1.300.000 I.U./Kg) on the ECoG of rabbits was studied. A tendency to an increase in spindling activity together with the presence of characteristic penicillin spikes, polyspikes and spike and wave complexes often preceding or intermixed to the spindling activity, was the most prominent finding. These data indicate that spindles and penicillin induced spikes show a straight correlation and seem consistent with the hypothesis that spindles have a facilitant effect on epileptic discharges.

Animals↗
PubMed1982

Influence of clonazepam and ethosuximide on ECoG pattern induced by metrazol during ontogenesis in rats.

Metrazol (80 mg/kg s. c.) elicited ECoG episodes of rhythmic activity the shape, frequency and localization of which depended on the age of rats. In 15- and 12-day-old animals there was a progression into sustained ictal activity. Clonazepam (1 mg/kg i. p.) exhibited excellent anti-metrazol action in adult, 25- and 12-day-old rats. The results in 15-day-old animals were inconsistent. Ethosuximide (125 mg/kg i. p.) protected sufficiently only adult and 25-day-old rats. In younger age groups only ictal activity was blocked, while metrazol-induced episodes remained untouched.

Age Factors↗